Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly

Journal of Endocrinological Investigation

Volumn 22, Issue 1, 1999, Pages 40-47

  Colao, Annamaria ^a   Marzullo, P ^b   Ferone, D ^b   Marino V ^b   Pivonello, R ^b   Di Somma, C ^b   Di Sarno, A ^b   Giaccio, A ^b   Lombardi, G ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Acromegaly; GH; IGF I; Lanreotide; Octeotide; Pituitary adenomas; Somatostatin analogs

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SLOW REACTING SUBSTANCE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE;

ABDOMINAL DISCOMFORT; ACROMEGALY; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GALLSTONE; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; STEATORRHEA; TIME; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 0033047214     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345477     Document Type: Article

References (30)

1. Melmed S. Acromegaly Engl. J. Med. 322: 966, 1990.
2. Frohman L.A. Therapeutic options in acromegaly. J. Clin. Endocrinol. Metab. 72: 1175, 1991.
3. Melmed S., Ho K., Klibanski A., Reichlin S., Thorner M. Recent advances in pathology, diagnosis and management of acromegaly. J. Clin. Endocrinol. Metab. 80: 3395, 1995.
4. Clayton R.N. New developments in the management of acromegaly. Should we achieve absolute biochemical cure? J. Endocrinol. 755: S23, 1997.
5. Melmed S., Dowling H., Frohman L., Ho K., Lamberts S.W.J., LaMont J.T., Sassolas G., Schoenfield L., Snyder PJ., Wass J.A.H. Consensus statement: benefits versus risks of medical therapy for acromegaly. Am. J. Med. 97: 468, 1994.
6. Lamberts S.W.J., van Der Lely A.J., de Herder W.W., Hofland J. Octreotide. N. Engl. J. Med. 334: 246, 1996.
7. Sassolas G., Harris A.G., James-Deidier A. Long-term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J. Clin. Endocrinol. Metab. 71: 391, 1990.
8. Vance M.L., Harris A.G. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Arch. Intern. Med. 151: 1573, 1991.
9. Newmann C.B., Melmed S., Snyder P.J., Young W.F., Boyajy L.D., Levy R., Stewart W.N., Klibanski A., Molitch M.E., Gagel R.F. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. J. Clin. Endocrinol. Metab. 80: 2768, 1995.
10. Arosio M., Macchelli S., Rossi C.M., Casati G., Biella O., Faglia G. Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study. Italian Multicenter Octreotide Study Group. Eur. J. Endocrinol. 133: 430, 1995.
11. Heron I., Thomas F., Dero M., Cancel A., Ruiz J.M., Schatz B., Kuhn J.M. Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. J. Clin. Endocrinol. Metab. 76: 721, 1993.
12. Caron P., Morange-Ramos I., Cogne M., Jaquet P. Three years follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab. 82: 18, 1997.
13. Giusti M., Gussoni G., Cuttica C.M., Giordano G., and the Italian multicenter slow-release lanreotide study group. Effectiveness and tolerability of slow-release lanreotide treatment in active acromegaly: six-month report on a Italian multicenter study. J. Clin. Endocrinol. Metab. 81: 2089, 1996.
14. Marek J., Hana V., Krsek M., Justova V., Catus F., Thomas F. Long-term treatment of acromegaly with the slow-release somatostatin analogue lanreotide. Eur. J. Endocrinol. 131: 20, 1994.
15. Morange I., De Boisvilliers F., Chanson P., Lucas B., Dewailly D., Catus F., Thomas F., Jaquet P. Slow-release lanreotide treatment in acromegalic patients previously normalized by octreotide. J. Clin. Endocrinol. Metab. 79: 145, 1994.
16. Chiodini P.G., Attanasio R., Cozzi R., Dallabonzana D., Oppizzi G., Orlandi P., Strada S., Liuzzi A. CV 205-502 in acromegaly. Acta Endocrinol. (Copenh.) 128: 389, 1993.
17. Lombardi G., Colao A., Ferone D, Sarnacchiaro F., Marzullo P., Di Sarno A., Rossi E., Merola B. CV 205-502 treatment in therapy-resistant acromegalic patients. Eur. J. Endocrinol. 132: 559, 1995.
18. Colao A., Ferone D., Marzullo P., Di Sarno A., Cerbone G., Sarnacchiaro F., Cirillo S., Merola B., Lombardi G. Effect of different dopaminergic agents in the treatment of acromegaly. J. Clin. Endocrinol. Metab. 82: 518, 1997.
19. Ferrari C., Paracchi A., Romano C., Gerevini G., Boghen M., Barreca A., Fortini P., Dubini A. Long-lasting lowering of serum growth hormone and prolactin levels by single or repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin. Endocrinol. (Oxf.) 29: 467, 1988.
20. Jackson S.N.J., Fowler J., Hewlett T.A. Cabergoline treatment of acromegaly: a preliminary dose finding study. Clin. Endocrinol. (Oxf.) 46: 745, 1997.
21. Abs R., Versholst J., Maiter D., et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J. Clin. Endocrinol. Metab. 83: 374, 1998.
22. Bevan J.S., Webster J., Burke C.W., Scanlon M.F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13: 220, 1992.
23. Chiodini P.G., Cozzi R., Dallabonzana D., Oppizzi G., Verde G., Petroncini M., Liuzzi A., Del Pozo E. Medical treatment of acromegaly with SMS 201-995, a somatostatin analogue: a comparison with bromocriptine. J. Clin. Endocrinol. Metab. 64: 447, 1987.
24. Fløgstad A.K., Halse J., Grass P., Abish E., Djøseland O., Kutz K., Bodd E., Jervell J. A comparison of octreotide, bromocriptine, or a combination of both drugs in acromegaly. J. Clin. Endocrinol. Metab. 79: 461, 1994.
25. Lamberts S.W.J., Zweens M., Verschoor L., del Pozo E. A comparison among the growth hormone lowering effect of the somatostatin analog, SMS 201-995, bromocriptine and combination of both drugs. J. Clin. Endocrinol. Metab. 63: 16, 1986.
26. Fløgstad A.K., Halse J., Bakke S., Lancranjan I., Marbach P., Bruns Ch., Jervell J. Sandostatin LAR in acromegalic patients: long-term treatment. J. Clin. Endocrinol. Metab. 82: 23, 1997.
27. Lancranjan I., Bruns C., Grass P., Jaquet P., Jervell J., Kendall-Taylor P., Lamberts S.W., Marbach P., Orskov H., Pagani G., Sheppard M., Simionescu L. Sandostatin-LAR®: a promising therapeutic tool in the management of acromegalic patients. Metabolism 45: 67, 1996.
28. Gillis J.C., Noble S., Goa K.L. Octreotide long-acting release (LAR). A review of its pharmacological properties and therapeutic use in the management of acromegaly. Drugs 53: 681, 1997.
29. Colao A., Ferone D., Lastoria S., Marzullo P., Cerbone G., Di Samo A., Longobardi S., Merola B., Salvatore M., Lombardi G. Prediction of efficacy of octreotide therapy in patients with acromegaly. J. Clin. Endocrinol. Metab. 81: 1356, 1996.
30. Colao A., Merola B., Ferone D., Lombardi G. Acromegaly. J. Clin. Endocrinol. Metab. 82: 2777, 1997.